Highly purified fucosylated chondroitin sulfate oligomers with selective intrinsic factor Xase complex inhibition
Copyright © 2019. Published by Elsevier Ltd..
Fucosylated chondroitin sulfate (FCS) oligosaccharides of specific molecular weight have shown potent anticoagulant activities with selectivity towards intrinsic factor Xase complex. However, the preparation of FCS oligosaccharides by traditional methods requires multiple purification steps consuming large amounts of time and significant resources. The current study focuses on developing a method for the rapid preparation of FCS oligomers from sea cucumber Pearsonothuria graeffei having 6-18 saccharide residues. The key steps controlling molecular weight (Mw) and purity of these FCS oligomers were evaluated. Structural analysis showed the resulting FCS oligomers were primarily l-Fuc3,4diS-α1,3-d-GlcA-β1,3-(d-GalNAc4,6diS-β1,4-[l-Fuc3,4diS-α1,3-]d-GlcA-β1,3-)nd-anTal-ol4,6diS (n = 1˜5) accompanied by partial de-fucosylation and/or de-sulfation. In vitro and in vivo experiments demonstrate that these FCS oligomers selectively inhibit intrinsic factor Xase complex and exhibit remarkable antithrombotic activity without hemorrhagic and hypotension side effects. This method is suitable for large-scale preparation of FCS oligosaccharides as clinical anticoagulants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:222 |
|---|---|
| Enthalten in: |
Carbohydrate polymers - 222(2019) vom: 15. Okt., Seite 115025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yan, Lufeng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2019 Date Revised 17.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.carbpol.2019.115025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29932589X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29932589X | ||
| 003 | DE-627 | ||
| 005 | 20231225100104.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.carbpol.2019.115025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0997.xml |
| 035 | |a (DE-627)NLM29932589X | ||
| 035 | |a (NLM)31320079 | ||
| 035 | |a (PII)S0144-8617(19)30692-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yan, Lufeng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Highly purified fucosylated chondroitin sulfate oligomers with selective intrinsic factor Xase complex inhibition |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2019 | ||
| 500 | |a Date Revised 17.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019. Published by Elsevier Ltd. | ||
| 520 | |a Fucosylated chondroitin sulfate (FCS) oligosaccharides of specific molecular weight have shown potent anticoagulant activities with selectivity towards intrinsic factor Xase complex. However, the preparation of FCS oligosaccharides by traditional methods requires multiple purification steps consuming large amounts of time and significant resources. The current study focuses on developing a method for the rapid preparation of FCS oligomers from sea cucumber Pearsonothuria graeffei having 6-18 saccharide residues. The key steps controlling molecular weight (Mw) and purity of these FCS oligomers were evaluated. Structural analysis showed the resulting FCS oligomers were primarily l-Fuc3,4diS-α1,3-d-GlcA-β1,3-(d-GalNAc4,6diS-β1,4-[l-Fuc3,4diS-α1,3-]d-GlcA-β1,3-)nd-anTal-ol4,6diS (n = 1˜5) accompanied by partial de-fucosylation and/or de-sulfation. In vitro and in vivo experiments demonstrate that these FCS oligomers selectively inhibit intrinsic factor Xase complex and exhibit remarkable antithrombotic activity without hemorrhagic and hypotension side effects. This method is suitable for large-scale preparation of FCS oligosaccharides as clinical anticoagulants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulant and antithrombotic activities | |
| 650 | 4 | |a Fucosylated chondroitin sulfate oligomers | |
| 650 | 4 | |a Intrinsic factor Xase complex | |
| 650 | 4 | |a Partial N-deacetylation–deaminative cleavage | |
| 650 | 4 | |a Ultrafiltration separation | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Neoplasm Proteins |2 NLM | |
| 650 | 7 | |a fucosylated chondroitin sulfate |2 NLM | |
| 650 | 7 | |a Factor VIIIa |2 NLM | |
| 650 | 7 | |a 72175-66-7 |2 NLM | |
| 650 | 7 | |a Chondroitin Sulfates |2 NLM | |
| 650 | 7 | |a 9007-28-7 |2 NLM | |
| 650 | 7 | |a Factor IXa |2 NLM | |
| 650 | 7 | |a EC 3.4.21.22 |2 NLM | |
| 650 | 7 | |a Cysteine Endopeptidases |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 650 | 7 | |a cancer procoagulant |2 NLM | |
| 650 | 7 | |a EC 3.4.22.26 |2 NLM | |
| 700 | 1 | |a Wang, Danli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Mengshan |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Yanlei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Fuming |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Xingqian |e verfasserin |4 aut | |
| 700 | 1 | |a Linhardt, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Shiguo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Carbohydrate polymers |d 1994 |g 222(2019) vom: 15. Okt., Seite 115025 |w (DE-627)NLM082819491 |x 1879-1344 |7 nnns |
| 773 | 1 | 8 | |g volume:222 |g year:2019 |g day:15 |g month:10 |g pages:115025 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.carbpol.2019.115025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 222 |j 2019 |b 15 |c 10 |h 115025 | ||